Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Molecular Pathology
What to consider in reporting germline VUS
September 2026—When Heidi Rehm, PhD, and other researchers examined more than 1.5 million diagnostic sequencing test results from 19 clinical laboratories, they found an astonishing rate of inconclusive reports due to variants of uncertain significance—nearly a third in diagnostic multigene panel testing.
AMP case report: Is undifferentiated sarcoma with EWSR1-POU5F1 fusion a molecularly defined entity?
September 2026—About 30 percent of soft tissue sarcomas are associated with chromosomal translocations leading to the formation of chimeric fusion genes that modify cellular function, leading to dysregulation of proliferation and resulting in clinically and genetically distinct neoplasms. EWSR1 is a commonly rearranged gene in sarcomas that can fuse as the 5’ partner with various genes. EWSR1-rearranged sarcomas include angiomatoid fibrous histiocytoma, clear cell sarcoma of soft parts, Ewing sarcoma, desmoplastic small round cell tumor (DSRCT), extraskeletal myxoid chondrosarcoma, myxoid liposarcoma, clear cell sarcoma-like tumors of the gastrointestinal tract, as well as round cell sarcoma with EWSR1-non-ETS fusions. Herein, we report an unusual case of EWSR1-POU5F1 fusion in an undifferentiated sarcoma. It has previously been described in myoepithelial tumors,3 but it has been described in undifferentiated sarcomas only a couple of times in the literature, to the best of our knowledge.
AMP case report: Therapy-related acute myeloid leukemia in a patient with BRCA1-positive breast cancer and a DDX41 possibly germline variant
August 2026—The 2022 World Health Organization and International Consensus Classification frameworks recognize several well-defined myeloid neoplasm categories that arise in the setting of inherited genetic predisposition. These entities are grouped according to associated clinical features and include myeloid neoplasms with germline predisposition in the absence of antecedent platelet abnormalities or organ dysfunction (e.g. CEBPA, DDX41, and TP53), those associated with inherited platelet disorders (e.g. RUNX1, ANKRD26, and ETV6), and disorders linked to underlying or potential organ dysfunction.
In select patients, taking aim at metastatic CRC
July 2026—Being able to distinguish the subset of patients with stage IV colorectal cancer who have a chance at cure with ablation or resection from those who do not has been the aim of two University of Chicago physicians who developed a biomarker for colorectal liver metastases called PersonaCRC.
AMP case report: Hypermutated stage IIC colon carcinoma with a rare POLE exonuclease variant and co-occurring MSH6 and PIK3CA alterations
July 2026—Colorectal carcinoma (CRC) with hypermutation is most commonly associated with DNA mismatch repair (MMR) deficiency; however, defects in DNA polymerase proofreading represent an important alternative mechanism. Recognition of POLE-driven hypermutation has diagnostic and therapeutic implications, particularly in microsatellite-stable CRC.
Early days for menin inhibitor monitoring
June 2026—In the cat-and-mouse maneuverings that often propel new cancer treatments, menin inhibitors are proving to be successful epigenetic therapies for acute leukemia. Last November brought FDA approval of revumenib for treatment of adults and children (one year and older) with relapsed or refractory acute myeloid leukemia with NPM1 gene mutations.
ESR1 mutation testing questions follow trial
May 2026—When it comes to cancer mutations, there are big fish in little ponds, and little fish in big ponds, and big fish in big ponds, and little fish in little ponds. The ESR1 mutation and its emergence in advanced breast cancer is still deciding what stripe of fish it is—or rather, breast specialists, researchers, and the FDA are in the midst of figuring out potentially important uses …
Experts talk sequencing platforms and pressures
May 2026—The fast-changing world of sequencing was the topic that a panel of pathologists and industry representatives dug into in a Feb. 27 online roundtable, led by CAP TODAY publisher Bob McGonnagle.
In brain tumors, new use for CSF cfDNA
April 2026—It’s hard to mount an argument against the Great Plains. Nor is there much reason to. But drive across eastern Colorado, Nebraska, Kansas, or the Dakotas, and it is a bona fide thrill to arrive in Wyoming’s northwest corner and see the Grand Tetons rising up in spectacular fashion.